[Clopidogrel versus acetylsalicylic acid in the secondary prophylaxis of vascular diseases. A commentary on the report of the Institute for Quality and Efficiency in the Health Service].
Mattle
Heinrich
H
Niederkorn
K
K
D000047:Academies and Institutes; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D000077144:Clopidogrel; D006801:Humans; D009313:National Health Programs; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011785:Quality Assurance, Health Care; D055502:Secondary Prevention; D013988:Ticlopidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014652:Vascular Diseases / Q000517:prevention & control*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D010975:Platelet Aggregation Inhibitors; D000077144:Clopidogrel; D013988:Ticlopidine; D001241:Aspirin